Paula Martinez Sanz, Dieke J van Rees, Lieke M J van Zogchel, Bart Klein, Panagiota Bouti, Hugo Olsman, Karin Schornagel, Ivana Kok, Ali Sunak, Kira Leeuwenburg, Ilse Timmerman, Miranda P Dierselhuis, Waleed M Kholosy, Jan J Molenaar, Robin van Bruggen, Timo K van den Berg, Taco W Kuijpers, Hanke L Matlung, Godelieve A M Tytgat, Katka Franke
BACKGROUND: Current immunotherapy for patients with high-risk neuroblastoma involves the therapeutic antibody dinutuximab that targets GD2, a ganglioside expressed on the majority of neuroblastoma tumors. Opsonized tumor cells are killed through antibody-dependent cellular cytotoxicity (ADCC), a process mediated by various immune cells, including neutrophils. The capacity of neutrophils to kill dinutuximab-opsonized tumor cells can be further enhanced by granulocyte-macrophage colony-stimulating factor (GM-CSF), which has been shown in the past to improve responses to anti-GD2 immunotherapy...
May 2021: Journal for Immunotherapy of Cancer